Phase 2 Regain Trial Crb3180015 Jrcts031190103 News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Second-line treatment with regorafenib displayed safety in patients with advanced hepatocellular carcinoma who were not eligible for treatment on the phase 3 RESORCE trial, according to data from the phase 2 REGAIN trial.

Comunidad autonoma de catalunaKeisuke korokiSchool of medicine at chiba universityDepartment of gastroenterologyInternational liver cancer association conferenceLiver cancer associationGraduate schoolChiba universityBarcelona clinic liver cancerHepatocellular carcinomaPhase 3 resorce trial nct01774344Phase 2 regain trial crb3180015 jrcts031190103